Avastin is an anticancer drug that refers to monoclonal antibodies.
Release form and composition
Avastin is produced in the form of concentrates, which are used for the preparation of infusion solutions:
- A solution of 100 mg / 4 ml in glass vials;
- A solution of 400 mg / 16 ml in glass vials.
The active ingredient of Avastin is bevacizumab.
Alpha-trehaloza dihydrate, sodium dihydrogen phosphate, sterile water, sodium hydrogen phosphate, polysorbate 20 serve as auxiliary substances.
Indications for use Avastin
According to the instructions, Avastin is shown when:
- Metastatic colorectal cancer (in combination with fluoropyrimidine);
- Colon cancer;
- Pancreatic cancer;
- Lung cancer (with metastases, common inoperable, recurrent non-small cell) in combination with platinum preparations;
- Metastatic cancer in mammology (in combination with capecitabine or paclitaxel);
- Renal cell carcinoma (metastatic, common) in combination with interferon alpha-2a;
- Primary peritoneal cancer (with pclisatel, carboplatin);
- Cancer of the fallopian tube;
- Ovarian cancer 3, 4 stages;
- Prostate cancer;
- Primary recurrence of fallopian tube cancer;
- The primary recurrence of epithelial ovarian cancer.
According to the instructions, Avastin should not be taken when:
- Hypersensitivity to the active or auxiliary components of the drug;
- Hypersensitivity to drugs based on Chinese hamster ovary cells and other recombinant human antibodies;
- Pregnancy and breastfeeding;
- Damage to metastases of the central nervous system;
- Hepatic or renal failure.
Avastin is not prescribed in childhood due to the lack of clinical trials for this age group.
Administration and dosage Avastin
The use of Avastin should be carried out only in / in the drip. It is forbidden to apply the medicine in / in the jet!
In case of metastatic colorectal cancer, Avastin is prescribed as the first line of therapy at a dose of 5 mg per kg of body weight every 2 weeks as a IV infusion for a long time.
As a second-line therapy, the dose of Avastin is 10 mg per kg of body weight once every 2 weeks in the form of intravenous infusion for a long time.
In case of metastatic breast cancer, Avastin is prescribed at a dose of 10 mg per kg of body weight once every 14 days as a IV infusion for a long time.
With a widespread inoperable metastatic or recurrent lung cancer, Avastin is used at a dose of 7.5–15 mg per kg of body weight as an intravenous infusion every 3 weeks for a long time in combination with chemotherapy.
In metastatic or advanced renal cell carcinoma, Avastin is prescribed at a dose of 10 mg per kg of body weight every 2 weeks for a long time.
With malignant glioma stage 4 (glioblastoma), Avastin treatment is carried out at a dose of 10 mg per kg of body weight once every 2 weeks for a long time.
According to the instructions, Avastin should be discontinued at the first signs of disease progression.
To prepare the Avastin solution, the required amount of the drug should be diluted in sodium chloride solution of 0.9% to a total volume of 100 ml.
The initial dose of the drug should be administered within 1.5 hours after chemotherapy, subsequent dosages can be administered before or after chemotherapy. If the patient has tolerated the first dose, the next dose can be administered for 1 hour, and the next dose for half an hour.
In elderly patients, dose adjustment Avastin is not required.
Side effects of Avastin
According to the instructions, Avastin can cause the following side effects from the various systems of vital activity of the body:
- Cardiovascular system: arterial thromboembolism, chronic heart failure, deep vein thrombosis, bleeding, supraventricular tachycardia;
- Hematopoietic system: neutropenia, leukopenia, anemia, thrombocytopenia;
- Gastrointestinal: constipation or diarrhea, abdominal pain, intestinal obstruction, perforation of the gastrointestinal tract, stomatitis, rectal bleeding, bleeding gums;
- Central nervous system: anorexia, taste distortion, syncope, peripheral sensory nephropathy, drowsiness, stroke, headache;
- Skin: dryness, discoloration, exfoliative dermatitis, hand-erythrosis syndrome;
- Respiratory: rhinitis, shortness of breath, nosebleeds, pulmonary thromboembolism, hypoxia;
- Visual organs: visual impairment;
- Other reactions: abscess, fever, urinary tract infections, vaginal bleeding, asthenia, sepsis, pain of different localization, fatigue.
On the laboratory side, the use of Avastin may cause the following deviations: proteinuria, hyperkalemia, hypokalemia, hypophosphatemia, hyponatremia, neutropenia, thrombocytopenia, hyperglycemia, an increase in prothrombin time.
When prescribing Avastin at a dose of 20 mg per kg of body weight, some patients reported severe migraine attacks.
According to the instructions, Avastin should be taken only under the supervision of the attending physician.
With the development of perforation of the gastrointestinal tract, Avastin should be discontinued.
If the patient has been treated with anthracyclines or taxanes for six months, the use of Avastin in combination with capecitabine is not recommended.
Analogs of Avastin
The structural analogue of Avastin for the active substance is the drug Bevacizumab.
Terms and conditions of storage
Avastin Bottles should be stored at 2-8 ° C. Do not freeze the medicine, shaking the vials is prohibited.
Shelf life of Avastin is 2 years.
The finished solution of Avastin can be stored for no longer than a day at a temperature of 2-8 ° C. Unused solution remaining in the vial should be destroyed as it contains no preservatives.